Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Some here are saying PTSC has more "say" in when TPL can license or not ...

Should the current goal of the PTSC BOD be to see the facts of the litigation after the Markman, only if the Markman is favorable, and make a decision on a firm settlement number that would make PTSC shareholders happy if they do in fact have substantial influence over final decisions regarding licensing?

50 to 100 million dollars publicized would go a long way as a settlement figure. More would be even better if possible.

How else can PTSC maximize MMP dollars for shareholders when Leckrone could be content with a 30 million dollar settlement?

GLTAL

Share
New Message
Please login to post a reply